INTRODUCTION
============

Fibromyalgia (FM) is characterized by widespread pain and other clinical manifestations such as sleep disturbance, fatigue, gastrointestinal symptoms, headache, and depression. It affects 2\~4% of the population \[[@B1][@B2]\]. Stress has been discussed as an etiological factor in the manifestation of chronic pain \[[@B3]\]. Stress can produce hyperalgesia (increased sensitivity to painful stimuli) or allodynia (pain triggered by innocuous stimuli) \[[@B4]\]. It has been reported that chronic pain or FM-like rodent model induced by intermittent cold stress (ICS) is useful for inducing abnormal pain, including mechanical allodynia and hyperalgesia \[[@B5]\]. Chronic restraint stress (CRS) can particularly cause neuronal damage, including atrophy of the hippocampus CA3 region. In addition, CRS can decrease neurogenesis and synaptic plasticity, thus resulting in impaired cognitive function \[[@B6][@B7]\]. Previous studies have demonstrated that emotional dysfunction induced by continuous pain is related to functional alterations in the medial prefrontal cortex, hippocampus, and striatum in rodents \[[@B8][@B9][@B10]\]. Moreover, mPFC and anterior cingulate cortex are involved in processing negative emotional components associated with pain \[[@B11]\].

FM-related pain is often treated by common painkillers such as non-steroidal anti-inflammatory drugs (NSAIDs) and opioids \[[@B12]\]. Other studies have demonstrated that antidepressants and antiepileptics such as gabapentin and pregabalin are effective for FM pain \[[@B13][@B14]\]. The efficacy of some classes of antidepressants has been proposed to involve increased phosphorylation of cAMP response element binding protein (CREB) which leads to increased expression of brain-derived neurotrophic factor (BDNF) \[[@B15]\]. BDNF is highly expressed in the hippocampus and the cerebral cortex where it contributes to neuronal development, growth, plasticity, survival, neuroprotection, and repair \[[@B16][@B17][@B18]\]. Antidepressant treatment can recover BDNF serum levels in depressed patients. In addition, BDNF levels are closely linked to chronic stress and psychiatric illnesses including depression \[[@B17][@B18][@B19]\]. Both serum and plasma BDNF concentrations are decreased in patients with major depressive disorder \[[@B20]\]. However, antidepressants can normalize these abnormalities \[[@B21]\]. It has been reported that rats exhibiting thermal hyperalgesia after loose ligation of the sciatic nerve have significant increase in BDNF levels in the lumbar spinal dorsal horn \[[@B22]\]. BDNF function is also strongly associated with the transmission of nociceptive information related to BDNF receptor tropomyosin receptor kinase (TrkB), extracellular signal regulated kinase (ERK), and CREB of ERK downstream target \[[@B23]\]. CREB is a transcription factor that plays a key role in adaptive neuronal responses. It also has complex functions in the regulation of learning and memory \[[@B23]\]. A recent study has suggested that CREB is phosphorylated at serine 133 (p-CREB) and activated upon stimulation of painproducing signals \[[@B24]\]. CREB seems to mediated by ERK \[[@B24]\]. Activated CREB can further induce the activation of c-Fos, a marker of neuronal activation within spinal nociceptive and brainstem pathways \[[@B24]\]. Furthermore, this pain pathway partly affects the efficiency of glutamatergic and GABAergic/glycinergic synapses \[[@B25]\]. It has been reported that repeated injection of specific antibody to BDNF can markedly suppress thermal hyperalgesia associated with increased levels of tropomyosin receptor kinase B (TrkB) receptor following sciatic nerve ligation in mice \[[@B26]\]. These findings have demonstrated that the release of endogenous BDNF may cause excitability of some neurons through activating TrkB receptor, resulting in neuropathic painlike state. The role of BDNF in pain state has received more attention as a neuromediator of hyperalgesia and spinal central sensitization \[[@B27][@B28]\]. It has been reported that infusion of BDNF into the midbrain can result in antidepressant-like effect in animal models \[[@B29]\]. Several additional tests have been conducted to determine whether BDNF infusions into hippocampus might result in behavioral effects \[[@B28][@B29]\]. Interestingly, hippocampal BDNF administration has antidepressant-like effects \[[@B30]\]. Furthermore, antidepressants can significantly increase the expression of BDNF in major subfields of the hippocampus, including the granule cell layer and CA1 and CA3 pyramidal cell layers \[[@B31][@B32]\]. It has been suggested that tianeptine may promote neuroplasticity by increasing BDNF expression which is decreased in animal models of stress involving CREB expression \[[@B33]\]. As one atypical antidepressant, tianeptine exhibits structural similarities to tricyclic antidepressants. Some antidepressants can affect presynaptic reuptake of serotonin and norepinephrine and increase their levels in the synaptic cleft \[[@B34]\]. Antinociceptive activity of tianeptine has been reported in animal models of acute nociception \[[@B35]\], morphine tolerance \[[@B36]\], and inflammatory pain \[[@B37]\]. Stress-induced morphological changes in the hippocampus are increased by some antidepressants such as tianeptine, lithium, and clomipramine \[[@B28][@B38][@B39]\]. Effects of tianeptine on nociception in mice have been investigated previously through thermal analgesic tests \[[@B35]\]. It has been reported that tianeptine has significant dose-dependent analgesic activity in mice \[[@B35]\]. Chronic tianeptine therapy can significantly decrease both apoptosis aggravated by stress and apoptosis in normal samples in the temporal cortex and hippocampus \[[@B40]\]. Furthermore, some clinical studies have indicated that tianeptine can be used to effectively treat somatic anxiety symptoms accompanying depression with possible anxiolytic effects \[[@B41][@B42][@B43]\].

Therefore, the objective of this study was to determine whether administration of tianeptine might have therapeutic efficacy in a FM mouse model. The model was constructed to evaluate the analgesic efficacy of tianeptine using behavioral pain tests involving either noxious or non-noxious mechanical (electronic von Frey filament) or thermal (tail flick test, plantar test) stimuli. Tail suspension test was used to evaluate the activity of depressant. We also examined the ability of tianeptine to modulate phosphorylated CREB (p-CREB) and BDNF expression in the mPFC and hippocampus of mouse.

METHODS
=======

Animals
-------

Male adult C57BL/6J mice were obtained from Daehan Biolink, Ink. (Eumsung, Chungbuk, Korea). They were housed in clear cages with free access to food and water. They were maintained on a 12:12 h light-dark cycle (lights on at 6:30 a.m.). All animal procedures were performed in accordance with the guidelines for the care and use of laboratory animals of the US National Institutes of Health. Animal protocols were approved by the Institutional Animal Care and Use Committee of Soonchunhyang University (Asan, Korea, SCH16-0061).

Drugs and treatments
--------------------

Tianeptine (Sigma-Aldrich, Seoul, Korea) was dissolved in 0.9% NaCl and injected intraperitoneally (10 mg/kg/daily once) for 24 days. Each drug treatment was performed every day at 10 a.m. during stress procedure.

Experimental model of fibromyalgia
----------------------------------

Adult mice were subjected to CRS as described previously \[[@B44][@B45]\]. Briefly, mice were restrained for 6 h (from 12 A.M. to 6 P.M.) daily in well-ventilated 50-ml conical tube without food or water. Control mice remained undisturbed in their home cages. Restraint stressor was proceeded for 21 days. Cold stress procedure was performed on stainless mesh plate in a cold room at 4℃ overnight (from 4:30 pm to 10:00 am). Environmental temperatures were alternated between 24℃ and 4℃ every 30 min from 10:00 am to 4:30 pm. These procedures were repeated for 2 days. On day 3, mice were adapted to 24℃ for 1 h before behavior test. We designated day 3 following the onset of cold stress exposure after day 21 of restraint stress. Control group mice were kept at 24℃ for all 3 days (from 4:30 pm on day 1 to 10:00 am on day 3) \[[@B46]\].

Behavioral tests
----------------

Behavior assessments were started one day after the last day of clod stress (N=10\~12 animals/group). Mice were allowed to acclimate to a testing room for at least 1 h before performing assessments. Modified behavioral tests including TST, TFT, PWL, and PWT were performed as described previously. In experiments of thermal and mechanical tests, thresholds were determined from three repeated challenges with 15 min intervals. Average values were used for statistical analysis.

Tail suspension test (TST)
--------------------------

TST has become one of the most widely used models for assessing depression-like behaviors in mice. Mice were subjected to short-term inescapable stress. Their tails were suspended to develop an immobile posture. The total duration of immobility induced by tail suspension was measured according to published procedures \[[@B47]\]. Mice were suspended 50 cm above the floor using adhesive tape placed approximately 1 cm from the tip of the tail. The total duration of immobility during a 6-min period was measured.

Tail flick test (TFT)
---------------------

TFT was used to assess the antinociceptive effect of drug by measuring the latency time \[[@B48][@B49]\]. Latency time is the time from the onset of radiant heat exposure to withdrawal of the tail. Thermal pain threshold of the tail was measured with a tail flick apparatus (IITC Inc., Woodland Hills, CA, USA). Each mouse was gently restrained under a 50-ml conical tube with light manual pressure to minimize stress. Radiant heat was applied to tail (2 cm distal part) of the animal and latency (in second) for the tail to flick away from the radiant heat was scored. A cutoff value of 20 sec of radiant heat application was used to avoid tissue damage to the tail. Each mouse was tested three times at each time point with an interval of 15 min between replicates. Three replicates were averaged to obtain tail withdrawal latency.

Paw withdrawal latency (PWL)
----------------------------

In PWL, the nociception threshold was assessed by latency time of paw withdrawal upon a thermal stimulus as described previously \[[@B50][@B51]\]. Mice were placed in individual clear plastic chamber on the top of a glass sheet and acclimated for 1 h. Radiant heat (IITC Inc., Woodland Hills, CA, USA) was positioned under a glass sheet. The projection bulb was focused on the plantar surface of the hind paw of the animal. Paw withdrawal latency defined as the first occurrence of licking the hind paw was scored. Each mouse was tested three times at each time point with an interval of 15 min between replicates. Three replicates were averaged to obtain paw withdrawal latency.

Paw withdrawal threshold (PWT)
------------------------------

The pressure needed to induce a flexor response was defined as the mechanical threshold. PWT was carried out using an electronic von Frey anesthesiometer (Anesthesiometer, IITC Inc., Woodland Hills, USA) as previously reported \[[@B52][@B53]\]. Mice were placed in a plastic chamber on a wire mesh grid floor and allowed to acclimate for 1 h. The maximum response threshold was set at rigid tip to prevent tissue damage.

Measurement of corticosterone
-----------------------------

After behavior tests, experimental subjects were placed in 50-ml conical tubes for 60 min \[[@B54]\]. Mice were decapitated rapidly at the end of the stress test and trunk blood (about 1 ml) was collected into centrifugal tubes. Blood samples were centrifuged (12,000 rpm, 10 min) to separate serum for corticosterone assay. Serum samples were stored at −80℃ until assay. Serum corticosterone levels were determined using Corticosterone ELISA Kit (Cayman chemical, Cat No. 501320; Ann Arbor, MI, USA). Assays were conducted according to the manufacturer\'s protocol.

Western blot
------------

Whole tissue of medial prefrontal cortex (mPFC) and hippocampus were lysed in RIPA buffer containing protease inhibitors, leupeptin, and sodium fluoride followed by centrifugation at 14,000 rpm for 10 min at 4℃ (N=6\~7 animals per group). Protein samples (100 µg) were electrophoretically separated on 15% sodium dodecyl sulfate-polyacrylamide gel and transferred to polyvinylidene difluoride membrane (Millipore, Milford, MA, USA). After blocking with 5% skim milk, membranes were probed with anti-phospho-CREB (p-CREB; 1:1,000; Cell Signaling Technology, Danvers, MA, USA), anti-CREB (CREB; 1:1,000; Cell Signaling Technology, Danvers, MA, USA), anti-BDNF (BDNF; 1:3,000; Abcam, Cambridge, UK), or anti-β-tubulin (Tubb; 1:3,000; Thermo Fisher Scientific, Inc., Rockford, IL) antibody overnight at 4℃. After washing with PBS three times, membranes were then incubated with peroxidase-conjugated secondary rabbit antibody (1:5,000; Abfrontier. Geumcheon-gu, Seoul, Korea) at room temperature for 1 h. Immunoreactive bands were detected using enhanced chemiluminescence kit (ELPIS-Biotech Inc., Daejeon, Korea). Quantitative measurements of p-CREB, CREB, BDNF, and β-tubulin proteins were obtained using ImageJ software (<http://imagej.nih.gov/ij>).

Immunohistochemistry
--------------------

Mice were perfused through the left cardiac ventricle with 4% paraformaldehyde. Fixed brains were removed, frozen, and cut into 30-µm sections (N=4\~5 animals/group). Frozen sections from the hippocampus were treated with 0.3% hydrogen peroxide (H~2~O~2~) for 5 min followed by blocking with normal horse serum. They were then incubated with anti-phospho-CREB (p-CREB1:800; Cell Signaling Technology, Danvers, MA, USA), anti-CREB (CREB; 1:800; Cell Signaling Technology, Danvers, MA, USA), and Cy3-conjugated anti-rabbit or anti-mouse secondary antibodies (1:500; Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA). After washing with PBS, sections were stained with 4\'6-diamidino-2-phenylindole (DAPI) to identify nuclei. Fluorescent images were captured using a confocal laser-scanning microscope (FV10-ASW; Olympus; Tokyo, Japan). Images were quantified with Image J software (<http://imagej.nih.gov/ij>) using a protocol described previously \[[@B55]\] with slight modifications.

Statistical analysis
--------------------

All data are expressed as means±standard deviation and/or standard error of the mean. Results between groups were compared using Student\'s *t*-test. All statistical analyses were performed using IBM SPSS Statistics 19 software (SPSS Inc, Chicago, IL, USA). A p-value of less than 0.05 was considered as statistically significant.

RESULTS
=======

Corticosterone
--------------

Corticosterone levels were significantly (p\<0.001) increased in the FM group compared to those in the control group ([Fig. 1](#F1){ref-type="fig"}). Corticosterone levels in tianeptine-administered FM group were decreased (p\<0.001) to levels similar to those in the control group ([Fig. 1](#F1){ref-type="fig"}).

Tail suspension test
--------------------

In TST, the duration of immobility was measured to determine stress-related despairing status in mice. The immobility time of mice in the FM group was significantly (p\<0.05) longer than that in the control group ([Fig. 2](#F2){ref-type="fig"}). After tianeptine administration, the immobility time was significantly (p\<0.01) shorter compared to that in the FM group ([Fig. 2](#F2){ref-type="fig"}), suggesting that tianeptine could reverse the despairing status in the FM group.

Tail flick test: tail-flick latency
-----------------------------------

The tail-flick latency was significantly different among the control group, FM group, and tianeptine-administered FM group in the 2 cm distal part of the tail ([Fig. 3](#F3){ref-type="fig"}). The FM group showed significant (p\<0.01) decrease in tail-flick latency compared to the control group ([Fig. 3](#F3){ref-type="fig"}). Such decrease in latency was recovered (p\<0.01) in the tianeptine-administered FM group ([Fig. 3](#F3){ref-type="fig"}).

Plantar test: paw withdrawal latency
------------------------------------

Significant differences in PWL were found among the control, FM, and tianeptine-administered FM groups for both right and left paws ([Fig. 4](#F4){ref-type="fig"}). The FM group exhibited significant (p\<0.01) decrease in PWL compared to the control group ([Fig. 4](#F4){ref-type="fig"}). Such decrease in PWL in the plantar test was recovered (p\<0.01) in the tianeptine-administered FM group ([Fig. 4](#F4){ref-type="fig"}).

Von Frey test: paw withdrawal threshold
---------------------------------------

Tianeptine-administration showed beneficial effects on the PWT for both right and left paws ([Fig. 5](#F5){ref-type="fig"}). The FM group exhibited significant (p\<0.01) decrease in PWT compared to the control group ([Fig. 5](#F5){ref-type="fig"}). Such decrease in response time in the FM group was recovered (p\<0.01) in the tianeptine-administered FM group ([Fig. 5](#F5){ref-type="fig"}).

Western blot and immunohistochemistry
-------------------------------------

The BDNF-CREB pathway is known to be related to depression and pain \[[@B56]\]. To determine whether BDNF-CREB pathway was involved in behavioral abnormalities of the FM group, the mPFC and hippocampus areas from the brains of the control, FM, and tianeptine-administered FM groups were subjected to Western blot analyses and immunohistochemical analyses. Western blot analyses results ([Fig. 6](#F6){ref-type="fig"}) revealed that protein levels of BDNF and p-CREB in the mPFC and hippocampal in the FM group were significantly (p\<0.05) lower than those in the control group. These changes were restored (p\<0.05) by tianeptine administration ([Fig. 6](#F6){ref-type="fig"} and [Fig. 7](#F7){ref-type="fig"}). Immunohistochemistry-stained brain images ([Fig. 7](#F7){ref-type="fig"}) revealed that BDNF and p-CREB were differentially expressed among the control, FM, and tianeptine-administered FM groups. Intensity values of immunohistochemical staining between control and FM groups or between FM and FM-TIA groups were significantly (p\<0.05) different ([Fig. 8](#F8){ref-type="fig"}).

DISCUSSION
==========

Previous investigations have implicated that changes in central nervous system circuitry are the underlying mechanisms of stress-induced hyperalgesia \[[@B57]\]. BDNF is one of the most extensively investigated proteins in brain plasticity. It has been proposed that BDNF participates in hypothalamic-pituitary-adrenal (HPA) axis activity by stress \[[@B58]\]. Reduced BDNF expression contributes to structural anomalies and functional impairment in local brain legions. Other studies have shown that a variety of drugs can concurrently increase p-CREB and BDNF levels in rat hippocampus \[[@B59]\]. Increased expression and activation of CREB has been linked to BDNF of hippocampus \[[@B31]\]. Our FM-like animal model showed increased immobility time in TST but decreased mechanical and thermal thresholds based on results of TST, TFT, PWT, and PWL. These changes were accompanied by decreased levels of BDNF expression and phosphorylation of CREB in the hippocampus and mPFC. Mice exhibited significant changes in serum corticosterone levels after 1 h of restraint stress. However, these changes were reversed by tianeptine administration. Tianeptine treatment was able to normalize both behavioral and protein alterations elicited by stress. Results of this study demonstrated that stress-induced corticosterone level might be related to abnormal pain behavior through BDNF-CREB signaling. Depression symptoms are frequently reported to be associated with disturbed glucocorticoid secretion in patients with depression and in many animal models of depression \[[@B60]\]. Therefore, dysfunction of the HPA axis has been investigated through assessment of serum corticosterone level \[[@B60]\]. In this study, FM animal model showed significant increase in serum corticosterone level in response to stress, indicating hyperactivity in the HPA axis, consistent with results of many previous studies \[[@B61][@B62]\].

Antidepressants block changes that contribute to long-term nociceptive sensory plasticity in the spinal cord and limbic regions involved in the modulation of affect \[[@B63][@B64]\]. Recommended pharmacotherapy for neuropathic pain includes the use of some antidepressants such as tricycle antidepressant (TCAs) or serotonin and noradrenaline re-uptake inhibitors \[[@B65]\]. Antidepressant drugs require chronic treatment to control neuropathic pain, suggesting recruitment of secondary downstream mechanisms and long-term molecular mechanisms. In TST of this study, tianeptine improved stress-induced depressive status, in correlation with BDNF and CREB results. In TFT and PWL, tianeptine reversed stress-induced thermal and mechanical hyperalgesia because it increased the latency time in radiant heat application. In the PWT test, tianeptine exerted the maximum threshold in mice. Among various TCAs, amitriptyline is the most studied and the most prescribed TCA clinically. It has efficacy for several neuropathic pain conditions, including postherpetic neuralgia and central pain \[[@B66]\]. Unlike classical analgesics, the effect of antidepressants on neuropathic pain is observed after prolonged treatment \[[@B67]\]. Selective serotonin reuptake inhibitors such as fluoxetine, paroxetine, and citalopram have been used for painful diabetic neuropathy \[[@B66][@B68][@B69]\]. The analgesic effect of tianeptine was also confirmed in our animal model, suggesting that tianeptine might have beneficial effect on pain-depression syndrome. Results of the present study confirmed that stressful exposure could impair pain-related symptoms via BDNF-CREB pathway in FM animal model.

In conclusion, tianeptine treatment can rescue repeated stress-induced depression and pain symptoms through activating the BDNF-CREB pathway. Our results provide a potential mechanistic explanation for the pathophysiology of FM with depressive symptoms and enhanced pain.
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![Corticosterone concentration changes after stressful paradigm.\
Corticosterone secretion was induced by restraint stress in FM mice (n=7 per group). Corticosterone level was expressed in concentration of pg/ml. Data are presented as means±SEM (^\*^p\<0.05 vs. CON; ^†^p\<0.05 vs. FM). FM, Fibromyalgia animal model; CON, non-FM animal model; FM-TIA, Tianeptine administered FM model.](kjpp-21-361-g001){#F1}

![Effect of tianeptine on immobility time in mice subjected to tail suspension test.\
The total duration of immobility during a 6-min period was measured (n=7 per group). Data are presented as means±SEM (^\*^p\<0.05 vs. CON; ^†^p\<0.05 vs. FM). FM, Fibromyalgia animal model; CON, non-FM animal model; FM-TIA, Tianeptine administered FM model.](kjpp-21-361-g002){#F2}

![Effect of tianeptine on nociceptive response via tail flick test in FM model.\
Latency time of tail flicking away from radiant heat was scored (n=7 per group). Comparison was made between Con and FM groups. Data are presented in second as means±SEM (^\*^p\<0.05 vs. CON; ^†^p\<0.05 vs. FM). FM, Fibromyalgia animal model; CON, non-FM animal model; FM-TIA, Tianeptine administered FM model.](kjpp-21-361-g003){#F3}

![Effect of tianeptine on nociceptive response in FM model.\
(A) Results of the right hind paw. (B) Results of the left hind paw. Thermal pain threshold was assessed via plantar test (n=7 per group). Graphs are shown in means±SEM of response frequency to heat stimulation (^\*^p\<0.05 vs. CON; ^†^p\<0.05 vs. FM). PWL, paw withdrawal time; FM, Fibromyalgia animal model; CON, non-FM animal model; FM-TIA, Tianeptine administered FM model.](kjpp-21-361-g004){#F4}

![Effect of tianeptine on nociceptive response in FM model using digital von Frey.\
(A) Results of the right hind paw. (B) Results of the left hind paw. Withdrawal responses to von Frey filaments from both hind paws were counted and then expressed as an average in gram (n=7 per group). Comparison was made between CON and FM groups. Data are presented as means±SEM (^\*^p\<0.05 vs. CON; ^†^p\<0.05 vs. FM). PWT, paw withdrawal threshold; FM, Fibromyalgia animal model; CON, non-FM animal model; FM-TIA, Tianeptine administered FM model.](kjpp-21-361-g005){#F5}

![Western blot analysis of BDNF, p-CREB, and CREB in mPFC.\
(A) Expression levels of BDNF, p-CREB, and CREB were detected by western blot analysis using anti-β-tubulin antibody as an internal control. Graph demonstrating the ratio of p-CREB or BDNF to Tubb. (B\~D) Quantitative analysis of western blot results for BDNF, pCREB, CREB expression levels in the medial prefrontal cortex (^\*^p\<0.05 vs. CON; ^†^p\<0.05 vs. FM). FM, Fibromyalgia animal model; CON, non-FM animal model; FM-TIA, Tianeptine administered FM model.](kjpp-21-361-g006){#F6}

![Western blot analysis of BDNF, p-CREB, and CREB in hippocampus.\
(A) Expression levels of BDNF, CREB, and CREB were detected by western blot analysis using anti-β-tubulin antibody as an internal control. Graph demonstrating the ratio of p-CREB or BDNF to Tubb quantified using ImageJ software. (B\~D) Quantitative analysis of western blot results of BDNF, pCREB, an CREB in the hippocampus (^\*^p\<0.05 vs. CON; ^†^p\<0.05 vs. FM). FM, Fibromyalgia animal model; CON, non-FM animal model; FM-TIA, Tianeptine administered FM model.](kjpp-21-361-g007){#F7}

![Patterns of p-CREB expression across the hippocampus in the FM model and tianeptine-administered FM model group.\
(A) Immunohistochemistry analysis showing p-CREB immunoreactivity in the hippocampus. Confocal microscopy image showed immunofluorescent staining for p-CREB (anti-p-CREB, red, Cy3) with DAPI (blue) in CA3 region of hippocampus. Scale bar, 50 µm. (B) Optical densities of p-CREB signals in immunostained hippocampus sections (^\*^p\<0.05 vs. CON; ^†^p\<0.05 vs. FM). (C) Confocal microscopy image showing immunofluorescent staining for CREB (anti-CREB, red, Cy3) with DAPI (blue) in the hippocampus. Scale bar, 50 µm. (D) Optical densities of CREB signals in immunostained hippocampus sections (^\*^p\<0.05 vs. CON; ^†^p\<0.05 vs. FM). Quantitative measurements of p-CREB, CREB, BDNF, and β-tubulin proteins were obtained using ImageJ software (<http://imagej.nih.gov/ij>). HIPP, hippocampus; FM, Fibromyalgia animal model; CON, non-FM animal model; FM-TIA, Tianeptine administered FM model; p-CREB, phospho CREB; CREB, cAMP response element-binding protein.](kjpp-21-361-g008){#F8}
